Bio-Techne Corporation (TECH) Jefferies London Healthcare Conference 2025 November 20, 2025 7:30 AM EST
Company Participants
James Hippel – Executive VP of Finance & CFO
Conference Call Participants
Tycho Peterson
Tycho Peterson
Presentation
Tycho Peterson
Okay. Great. We’re going to kick it off. I’m Tycho Peterson from the Life Science team. We’re pleased to have Bio-Techne with us today. Welcome.
Question-and-Answer Session
Tycho Peterson
Maybe kick off with a little just a quick look back on the fiscal first quarter, some gives and takes, but you did talk about kind of core growth up 1%, maybe setting aside the cell therapy kind of noise here. We’ll unpack that in a minute, but just talk a little bit about what you saw in the quarter.
James Hippel
Executive VP of Finance & CFO
Tycho, thanks for having us. Yes, the overall growth for the quarter was negative 1%, a little bit — a result that doesn’t really reflect our underlying performance because you already mentioned we were 1% positive if you take 2 larger companies that received their Fast Track designation and therefore, didn’t order this year compared to last year, and that really drove a negative 200 basis points on the top line.
But underlying, if you think about the end markets as well as our 4 growth verticals, the end markets that did do a little bit better than we had expected was definitely large pharma, 30% of our revenues, and we continue to be in the double digits performance there. And last year, we — or last quarter, we were actually a little worried about the rhetoric with some of the tariffs and most people were pricing that we were worried that they would tap the brakes, but they didn’t. And that was a positive for a quarter.
Read the full article here